Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bayer Schering Aims at Becoming One of World's Top-Five Oncology Companies: Mr R. Rosen
August 3, 2009
- Generic Firms Should Ally to Improve Image of Generics: Mr Kinoshita
August 3, 2009
- Chugai Keeps Top Position in Japanese Oncology Market
August 3, 2009
- Hodanren Opposed to Promotion of Use of Generics That Neglect Reality
August 3, 2009
- NBI Aims at Sales of ¥17 Bil. for Spiriva
August 3, 2009
- JLHWO to Conduct More Clinical Trials at Rosai Hospitals
August 3, 2009
- Recomodulin to Grow Big in FY2011: Asahi Kasei Pharma
August 3, 2009
- R&D NEWS IN BRIEF
August 3, 2009
- Kyowa Kirin to Increase Focus on Diagnostics: Dr Matsuda
August 3, 2009
- Reports of Malfunctions from Marketers Show Sharp Decrease in FY2008
August 3, 2009
- Nippon Chemiphar to Decide Its Relationship with Ranbaxy Soon
August 3, 2009
- MEDICAL DEVICE NEWS IN BRIEF
August 3, 2009
- Patients, Doctors Remain Calm Despite EASD Reports on Lantus: sanofi-aventis
July 27, 2009
- Cravit No. 1 on HP Market, No. 2 on GP Market: Rep Track Survey
July 27, 2009
- Merck Serono Aims at Becoming No. 1 in Reproductive Health, Metabolic Oncology
July 27, 2009
- Hisamitsu to Acquire Noven Pharm. to Strengthen US Business Platform
July 27, 2009
- Immunology/Inflammation MTPC's 3rd Top-Priority Field
July 27, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 27, 2009
- Nat'l Univ. Hospitals Apprehensive of Negative Effects of Use of Generics on Their Research
July 27, 2009
- R&D NEWS IN BRIEF
July 27, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…